| dbo:abstract
|
- Tirbanibulin, vermarktet unter dem Markennamen Klisyri (Almirall), ist ein Arzneistoff zur Behandlung von aktinischer Keratose im Gesicht oder auf der Kopfhaut. Es wirkt als Mitosehemmer. (de)
- Tirbanibulin, sold under the brand name Klisyri, is a medication for the treatment of actinic keratosis (AKs) on the face or scalp. The most common side effects include local skin reactions, application site pruritus, and application site pain. Tirbanibulin was approved for medical use in the United States in December 2020, and in the European Union in July 2021. The U.S. Food and Drug Administration (FDA) considers it to be a first-in-class medication. It functions as a mitotic inhibitor by inhibiting tubulin polymerization and Src kinase signaling can be potentially effective in deferring the development of AKs to squamous cell carcinoma in situ. (en)
|
| dbo:alternativeName
| |
| dbo:casNumber
| |
| dbo:chEMBL
| |
| dbo:class
| |
| dbo:drugbank
| |
| dbo:fdaUniiCode
| |
| dbo:kegg
| |
| dbo:pubchem
| |
| dbo:thumbnail
| |
| dbo:wikiPageExternalLink
| |
| dbo:wikiPageID
| |
| dbo:wikiPageLength
|
- 11363 (xsd:nonNegativeInteger)
|
| dbo:wikiPageRevisionID
| |
| dbo:wikiPageWikiLink
| |
| dbp:atcPrefix
| |
| dbp:atcSuffix
| |
| dbp:c
| |
| dbp:casNumber
| |
| dbp:chembl
| |
| dbp:chemspiderid
| |
| dbp:class
| |
| dbp:dailymedid
| |
| dbp:drugbank
| |
| dbp:h
| |
| dbp:iupacName
|
- N-benzyl-2-[5-[4-phenyl]pyridin-2-yl]acetamide (en)
|
| dbp:kegg
| |
| dbp:legalEu
| |
| dbp:legalUs
| |
| dbp:n
| |
| dbp:o
| |
| dbp:pdbLigand
| |
| dbp:pubchem
| |
| dbp:routesOfAdministration
| |
| dbp:smiles
| |
| dbp:stdinchi
| |
| dbp:stdinchikey
|
- HUNGUWOZPQBXGX-UHFFFAOYSA-N (en)
|
| dbp:synonyms
| |
| dbp:tradename
| |
| dbp:unii
| |
| dbp:width
| |
| dbp:wikiPageUsesTemplate
| |
| dcterms:subject
| |
| rdf:type
| |
| rdfs:comment
|
- Tirbanibulin, vermarktet unter dem Markennamen Klisyri (Almirall), ist ein Arzneistoff zur Behandlung von aktinischer Keratose im Gesicht oder auf der Kopfhaut. Es wirkt als Mitosehemmer. (de)
- Tirbanibulin, sold under the brand name Klisyri, is a medication for the treatment of actinic keratosis (AKs) on the face or scalp. The most common side effects include local skin reactions, application site pruritus, and application site pain. Tirbanibulin was approved for medical use in the United States in December 2020, and in the European Union in July 2021. The U.S. Food and Drug Administration (FDA) considers it to be a first-in-class medication. (en)
|
| rdfs:label
|
- Tirbanibulin (de)
- Tirbanibulin (en)
|
| owl:sameAs
| |
| prov:wasDerivedFrom
| |
| foaf:depiction
| |
| foaf:isPrimaryTopicOf
| |
| is dbo:wikiPageRedirects
of | |
| is dbo:wikiPageWikiLink
of | |
| is foaf:primaryTopic
of | |
